Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel method for treating ovarian cancer

10.08.2011
The Fraunhofer Institute for Cell Therapy and Immunology IZI supports the Australian company Prima BioMed Ltd. in tests and approvals regarding a novel therapeutic method for treating ovarian cancer.

Prima BioMed Ltd. is developing an autologous (the body's own) immune therapy for the treatment of epithelial ovarian carcinoma (ovarian cancer). Before the socalled CVac therapy can obtain approval and be used for treating patients, its safety and efficacy must be proved in a clinical study. According to Prima BioMed Ltd., first results of previous studies are highly promising.

Together with the Fraunhofer IZI the Australian company intends to conduct the clinical trial and to obtain approval for the novel therapy. In this context the Fraunhofer IZI is particularly responsible for the manufacture of investigational medicinal products and the conduct of quality controls for the European arm of the study. This joint project is funded with 4.1 million Euros by the Development Bank of Saxony (Sächsische Aufbaubank). On August 8, 2011, Saxonian State Minister Prof. Dr. Dr. Sabine von Schorlemer personally presented the funding grant, thus emphasizing the significance of such innovative projects for the Free State of Saxony.

In order to introduce the therapy to the European market as soon as possible, the Australian company has founded a German subsidiary based in Leipzig. Matthew Lehman, managing director of the Prima BioMed GmbH, is enthusiastic about the location of Leipzig. "The comprehensive support for Prima BioMed and our CVac program by the Free State of Saxony is overwhelming. With the Fraunhofer IZI, this region offers an advanced research infrastructure combined with excellent funding options through the Development Bank of Saxony, advantageous biologistics provided by the airport Leipzig-Halle and an outstanding research and development landscape. We are glad to be able to control our activities in Europe from Leipzig and are looking forward to a longterm commitment in this region".

Dr. Gerno Schmiedeknecht, Head of the Department of Cell Engineering at the Fraunhofer IZI, is glad about the cooperation. "We are proud to support Prima BioMed in the development of the CVacTM technology. It is our common goal to provide this promising therapy as soon as possible to as many patients as possible".

The autologous immune therapy CVacTM is based on the modification of the body's own immune cells. Tumor cells are capable of evading the immune defense in various ways. The CVacTM method modifies the patient's specialized immune cells so as to make them recognize the tumor cells and activate diverse defense mechanisms of the immune system. These so-called dendritic cells are targeted to recognize a specific protein (biomarker) that is present exclusively on the tumor cells. The immune system is thus capable of specifically attacking the tumor cells without affecting healthy cells. This form of treatment is therefore much gentler for the patient than irradiation and chemotherapies and also holds the promise of lower relapse rates.

| Fraunhofer-Institut
Further information:
http://www.izi.fraunhofer.de/
http://www.primabiomed.com.au/

Further reports about: BioMed CVac End User Development IZI cell death healthy cell immune cell immune system tumor cells

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>